[Combination immunization with EIAV Env protein expressed by recombinant baculovirus and recombinant vaccinia virus containing env gene].

The study aims to develop a new type of vaccine for Equine Infectious Anemia Virus (EIAV) and analyzes the impact of combining protein antigen and recombinant vaccinia virus to produce a higher neutralizing antibody rate. This research could potentially benefit the development of HIV vaccines in the future.

Research Methodology

• For developing an innovative vaccine candidate to combat the Equine infectious anemia virus (EIAV), researchers selected the Env genes from two strains: EIAV Chinese donkey leukocyte attenuated strain (EIAV DLV) and its parental virus strain (EIAV LN).
• With the help of the BAC-To-BAC system, these Env genes were expressed, and the presence of the Env proteins was confirmed using SDS-PAGE and Western blot methods.
• BALB/c mice were used as a model for the immunization process. They were administered with recombinant vaccinia viruses in which the env genes of EIAV were present, either alone or enhanced with Env proteins expressed via recombinant baculovirus.
• Afterward, the humoral and cellular immune responses in the mice were studied, contributing to the evidence of protective immune reactions.

Research Findings

• The use of recombinant baculovirus effectively led to the production of complete Env proteins. This was a significant step forward in the vaccine development.
• The study found that the titer of neutralizing antibody in the prime-boost group was significantly higher – between 5 to 9 times – than the rVV group. This indicates that combining the protein antigen with recombinant vaccinia virus can generate a stronger immune response against the EIAV.

Research Implications

• These findings suggest that a combination of protein antigen and recombinant vaccinia virus could lead to an effective vaccine strategy to induce higher rates of neutralizing antibodies against EIAV.
• This study could potentially pave the way for the development of a novel genetically engineered vaccine against EIAV. The impacts of this research are not limited to EIAV alone but may inform future advancements in developing an effective vaccine strategy for HIV.